Objective
to compare the safety and efficacy of ticagrelor with clopidogrel in patients with ACS
Study
multicentre, open-label randomised trial
Population
patients with ACS (with or without ST-Elevation) and intended invasive R x (85%)
Endpoints
clinically significant bleeding (composite of major or minor bleeding according to PLATO) at 12 months
Conclusion
ticagrelor was associated with a significant higher bleeding rate than clopidogrel in patients with ACS and intended invasive management
Park et al. Circulation. 2019;140:1865-77
